C-KIT gene mutations are not a rare event in Core Binding Factor Leukemia (CBFL). To investigate their prognostic impact in this setting , we attempted at correlating the KIT mutational status with the WBC count, the level of the WBC-index, the presence of extramedullary disease (EMD) and the outcome, in t(8;21)(n=30) and inv(16) (n=20) AML patients. On the basis of genomic DNA analysis of c-KIT gene exons 2, 8, 10, 11, 17 for mutation detection, we categorized 21 patients (42%) in the "KIT mutated group" (KIT+) and 29 patients (58%) in the "KIT unmutated group" (KIT–). The median age at diagnosis was 46.4 and 45.6 years for the KIT(+) and KIT(–) groups, respectively (P=0.872). Among the KIT(+) patients, we found mutations in exon 8 (n = 4), exon 10 (n =1), exon 11 (n = 1) and exon 17 (n = 15). We recorded mean WBC counts of 28.6 x 109/L vs 34.5 x 109/L (P=0.051), and a mean WBC-index, expressed as WBC x (% Bone Marrow blasts/100), of 37.2 vs 15.5 (P=0.0395), for KIT(+) and KIT(–), respectively. Seven out of 50 patients experienced an EMD: in 6 cases (28.57%) this event occurred in the KIT(+) group. 40 patients (age < 60 years) were evaluable for clinical response; 18 out of them were KIT mutated. At a median follow-up of 24 months (range 10–107), we recorded for KIT(+) and KIT(–), respectively: CR incidence of 88.8 % (16/18) vs 100% (22/22) (P=0.38); Relapse Incidence 81.3% (13/16) vs 31.81% (7/22), P=0.0072; OS 27.7% (5/18) vs 77.3% (17/22), P=0.0049; DFS 16.7% (3/18) vs 77.3% (17/22), P=0.0005. Using a log-it linear model for univariate and multivariate regression analysis, we found a significant contribution to death (P=0.048) and relapse (P= 0.045) exerted by mutation in the whole group of patients; this effect was more evident when the analysis was restricted to patients <60 years (P=0.003 and P=0.014, respectively). In conclusion, this study confirms the correlation between c-KIT mutational status and high WBC-index in CBFL patients. Furthermore, our data indicate a statistical correlation between the presence of c-KIT mutations and both the OS and the DFS.

Prognostic impact of C-KIT mutations in Core Binding Factor-Leukemia / R. Cairoli, A. Beghini, G. Nadali, F. Elice, M. Lunghi, A. Cuneo, G. Grillo, M. Michelatti, C.B. Ripamonti, M. Lazzarino, F. Rodeghiero, G. Pizzolo, L. Larizza, E. Morra. - In: BLOOD. - ISSN 0006-4971. - 104:11(2004 Nov), pp. 555A-555A. ((Intervento presentato al 46. convegno Annual Meeting of the American Society of Hematology tenutosi a San Diego nel 2004.

Prognostic impact of C-KIT mutations in Core Binding Factor-Leukemia

A. Beghini
Secondo
;
L. Larizza
Penultimo
;
2004

Abstract

C-KIT gene mutations are not a rare event in Core Binding Factor Leukemia (CBFL). To investigate their prognostic impact in this setting , we attempted at correlating the KIT mutational status with the WBC count, the level of the WBC-index, the presence of extramedullary disease (EMD) and the outcome, in t(8;21)(n=30) and inv(16) (n=20) AML patients. On the basis of genomic DNA analysis of c-KIT gene exons 2, 8, 10, 11, 17 for mutation detection, we categorized 21 patients (42%) in the "KIT mutated group" (KIT+) and 29 patients (58%) in the "KIT unmutated group" (KIT–). The median age at diagnosis was 46.4 and 45.6 years for the KIT(+) and KIT(–) groups, respectively (P=0.872). Among the KIT(+) patients, we found mutations in exon 8 (n = 4), exon 10 (n =1), exon 11 (n = 1) and exon 17 (n = 15). We recorded mean WBC counts of 28.6 x 109/L vs 34.5 x 109/L (P=0.051), and a mean WBC-index, expressed as WBC x (% Bone Marrow blasts/100), of 37.2 vs 15.5 (P=0.0395), for KIT(+) and KIT(–), respectively. Seven out of 50 patients experienced an EMD: in 6 cases (28.57%) this event occurred in the KIT(+) group. 40 patients (age < 60 years) were evaluable for clinical response; 18 out of them were KIT mutated. At a median follow-up of 24 months (range 10–107), we recorded for KIT(+) and KIT(–), respectively: CR incidence of 88.8 % (16/18) vs 100% (22/22) (P=0.38); Relapse Incidence 81.3% (13/16) vs 31.81% (7/22), P=0.0072; OS 27.7% (5/18) vs 77.3% (17/22), P=0.0049; DFS 16.7% (3/18) vs 77.3% (17/22), P=0.0005. Using a log-it linear model for univariate and multivariate regression analysis, we found a significant contribution to death (P=0.048) and relapse (P= 0.045) exerted by mutation in the whole group of patients; this effect was more evident when the analysis was restricted to patients <60 years (P=0.003 and P=0.014, respectively). In conclusion, this study confirms the correlation between c-KIT mutational status and high WBC-index in CBFL patients. Furthermore, our data indicate a statistical correlation between the presence of c-KIT mutations and both the OS and the DFS.
English
Settore MED/03 - Genetica Medica
Settore BIO/11 - Biologia Molecolare
Settore MED/15 - Malattie del Sangue
Riassunto di intervento a convegno
Esperti anonimi
nov-2004
104
11
555A
555A
Pubblicato
Periodico con rilevanza internazionale
Annual Meeting of the American Society of Hematology
San Diego
2004
46
info:eu-repo/semantics/article
Prognostic impact of C-KIT mutations in Core Binding Factor-Leukemia / R. Cairoli, A. Beghini, G. Nadali, F. Elice, M. Lunghi, A. Cuneo, G. Grillo, M. Michelatti, C.B. Ripamonti, M. Lazzarino, F. Rodeghiero, G. Pizzolo, L. Larizza, E. Morra. - In: BLOOD. - ISSN 0006-4971. - 104:11(2004 Nov), pp. 555A-555A. ((Intervento presentato al 46. convegno Annual Meeting of the American Society of Hematology tenutosi a San Diego nel 2004.
none
Prodotti della ricerca::01 - Articolo su periodico
14
266
Article (author)
si
R. Cairoli, A. Beghini, G. Nadali, F. Elice, M. Lunghi, A. Cuneo, G. Grillo, M. Michelatti, C.B. Ripamonti, M. Lazzarino, F. Rodeghiero, G. Pizzolo, L. Larizza, E. Morra
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/208904
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact